Fragment-Based
Drug Discovery of Phosphodiesterase
Inhibitors
Version 2 2017-08-11, 18:52
Version 1 2017-08-11, 15:44
Posted on 2017-08-11 - 18:52
Phosphodiesterases
are proving to be fruitful targets for drug
discovery. At the same time fragment-based drug discovery has matured
into a powerful and widely applied technique. In this communication
we review the application of fragment-based drug discovery for the
successful identification of novel 3′,5′-cyclic nucleotide
phosphodiesterase (PDE) inhibitors, concentrating on both experimental
and computational strategies for fragment screening and hit-to-lead
development. To this end, we also mine the open access databases ChEMBL
and PDB for fragments showing PDE inhibitory activity, as well as
SureChEMBL for recent PDE related patents, to provide a wider context
for exploring fragment diversity. Together these approaches form an
integrated experimental and computational platform to exploit fragment-based
drug discovery for this important gene superfamily.
CITE THIS COLLECTION
DataCite
3 Biotech
3D Printing in Medicine
3D Research
3D-Printed Materials and Systems
4OR
AAPG Bulletin
AAPS Open
AAPS PharmSciTech
Abhandlungen aus dem Mathematischen Seminar der Universität Hamburg
ABI Technik (German)
Academic Medicine
Academic Pediatrics
Academic Psychiatry
Academic Questions
Academy of Management Discoveries
Academy of Management Journal
Academy of Management Learning and Education
Academy of Management Perspectives
Academy of Management Proceedings
Academy of Management Review
Svensson, Fredrik; Bender, Andreas; Bailey, David (2017). Fragment-Based
Drug Discovery of Phosphodiesterase
Inhibitors. ACS Publications. Collection. https://doi.org/10.1021/acs.jmedchem.7b00404
or
Select your citation style and then place your mouse over the citation text to select it.
SHARE
Usage metrics
Read the peer-reviewed publication
AUTHORS (3)
FS
Fredrik Svensson
AB
Andreas Bender
DB
David Bailey